期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管生成抑制剂与肺癌治疗的研究进展

Progress of treatment of lung cancer with angiogenesis inhibitors
在线阅读 下载PDF
导出
摘要 目的:探讨血管生成抑制剂治疗肺癌的研究进展。方法:收集该类药物的国内外近期资料加以综合归纳。结果:血管生成抑制剂治疗肺癌方法可行,前景诱人。结论:随着血管生成抑制剂的不断开发和研究,对于肺癌这一血管增生明显的肿瘤,深入研究抗血管治疗具有重要意义。 objective： To discuss the progress angiogenesis inhibitors on treatment of lung cancer. Methods： Collecting and summarizing domestic and foreign data concerned recently. Results： Angiogenesis inhibitors have brighter prospects on treatment of lung cancers. Conclusion： Along with the investigation and exploitation of angiogenesis inhibitors, further research into treatments of antiangiogenesis takes on significant value for lung cancer that is characterized by obvious hyperplasia of blood vessel.
作者 赖泳 刘光明
机构地区 大理学院药学院
出处 《大理学院学报（综合版）》 CAS 2007年第6期58-60,共3页 Journal of Dali University
基金 国家自然科学基金资助项目(项目批准号:30560181)
关键词 肺癌 血管生成 抑制剂 lung cancer angiogenesis inhibitor
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献7

二级参考文献57

  • 1李忠义 陈林生 等.人血管内皮抑制素的基因克隆、表达及其抗肿瘤效应的研究[A]..中华医学会辽宁分会第六次微生物免疫学术会议文汇编[C].,2000.2-3.
  • 2[1]Eatock MM, Schatzlein A, Kaye SB. Tumor vasculature as a target for anticancer therapy [J]. Cancer Treat Rev, 2000; 26(3):191-204.
  • 3[2]Ostrowski K, Kinsner A. Inhibition of angiogenesis in the treatment of tumors [J]. Arch Immunol Ther Exp (Warsz), 2001; 49(1):27-31.
  • 4[3]Mikasa k, Sawaki M, Kita E, Hamada K, Konishi M, Meada K, Teramota S, Takeuchi S, Fukuoka K, Sakamoto M, Tsujimoto M, Mori K, Kunimatsu M, Kashiba S, Narita N. Clarithromycin in the long-term treatment of primary lung cancer: Possibility of clarithromycin as a biological response modifier [J]. Chemotherapy, 1994; 42(3):1293-1298.
  • 5[4]Konno SM, Adachi k, Asano T, Okamoto TK. Influence of roxithromycin on the cell-mediated immune responses [J]. Life Sci, 1992; 51(1):107-112.
  • 6[5]Mikasa K. Study of effects and mechanisms of macrolide as biological response modifier for lung cancer treatment [J]. Jpn J Antibiot, 2000; 53(4):253-260.
  • 7[6]Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor [J]. Lab Invest, 1992; 67(4): 519-528.
  • 8[7]Liu F, Zhang X, Bu XY, Yi SY, Zhang JN, Guo QD, Liu XZ, Song SJ. Tumor angiogenesis in meningioma in relation to peritumoral edema, recurrence and prognos [J]. Di-si Junyi Daxue Xuebao (J Fourth Mil Med Univ), 2001; 21(9):1153-1155.
  • 9[8]Bastaki M, Nelli EE, Dell'Era P, Rusnati M. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium: A study of aortic and microvascular endothelial cell lines [J]. Arterioscler Thromb Vasc Biol, 1997; 17(3):454-459.
  • 10[9]Yatsunami Jun, Turuta N, Wakamatsu K, Hara N, Hayashi S. Chlarithromycin is a potent inhibitor of tumor-induced angiogenesis [J]. Res Exp Med, 1997; 197(1): 189-197.

共引文献36

大理学院学报（综合版）
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部